" the answer to the need
for a standardized, integrated,
preventive supply chain
risk management system
in the market."


MYTIGATE will be a validated web-based platform for companies within the pharma supply chain which will support them to identify, analyze, evaluate and mitigate their Supply Chain Risk Management.
It´s the gate to a secure, economic, validate and digital Supply Chain Management.





...will identify, evaluate and digitize the service portfolio of the acting partners with their in-house- and external interfaces along the entire supply chain.

...will identify potential risks along the lanes in order to identify the transport routes and partners, with which the risks can be minimized.


MYTIGATE will provide pharmaceutical producer, wholesaler, forewarder and carrier with a list of supply chain partners and their capabilities along a specific lane. Based on this, the shipper will be able to select specific flight routes and service providers.

Furthermore, the shipper is able to use MYTIGATE with all his learning knowledge about theoretical risks, about experience-based knowledge form different partners (anonymized) and about root cause data for irregularities/deviations to qualify new routes and to evaluate which lane will be suitable for a particular purpose.

In addition, the information can also be used for certification and documentation to authorities.

Finally, service providers in the supply chain are offered quality audits to improve their performance and qualify as partners.


MYTIGATE is the answer to the need for a validated, integrated, preventive supply chain risk management system in the market

The German pharmaceutical industry is one of the most significant economic sectors in Germany with an overall turnover of 39.5 billion Euros in 2016. It significantly contributes to increasing the quality of life and the life expectancy of people with its products. The increasing globalization of production and distribution and the constantly changing conditions pose major challenges for the contributing parties in the pharma supply chain – the supply chain from the production all the way to the consumer.

The legal situation has become stricter over the past years: the responsibility for the quality of the production in the supply chain was made more transparent to the involved parties through the Good Distribution Practice (GDP) guidelines of the European Commission. The guidelines request a respective quality risk management from the pharmaceutical companies with the goal to achieve more safety and transparency along the supply chain. They determine that the planning of transportations for pharmaceutical products must consider possible risks in order to possibly avoid them. As a consequence, manufactures, wholesalers and logistics service providers want to make use of an intelligent IT system that comprehensively visualizes the transport chain in consideration of the increased safety.

Under the leadership of the Frankfurt UAS, the pharmaceutical companies will take a seat together with the involved partner companies and cooperate for the first time in order to work on a solution for a quality risk management. The goal of the project is the development of a web-based risk management IT tool which will allow pharmaceutical manufacturers to manage the pharma supply chain risk-oriented and which will help the companies in the network design (strategic level) along the pharma supply chain and while monitoring single shipments (tactical level). The tool is being developed by the German cynatics Consulting GmbH in collaboration with Frankfurt University of Applied Sciences, RheinMain University of Applied Sciences, Fulda University of Applied Sciences, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Frigo-Trans GmbH and GEFCO Forwarding Germany.

“We will identify, digitalize and thereby minimize risks in the supply chain with its complex network consisting of company-internal and external interfaces between manufacturers, suppliers and consumers together with our project partners in the frame of a comprehensive supply chain risk management. Similar risk models currently only exist in the finance sector. In the pharmaceutical field this is new territory”, says Ziegler. “There does not exist a similar IT tool in the pharma or logistics sector at the moment.” With the created digital solution, the path of a temperature-controlled pharmaceutical product from its production all the way to the consumer will be visible and can be planned in the future under the aspects of safety, growth and increased turnover.

“This increases the safety of the pharmaceutical products and protects the consumer”, says Ziegler. The IT tool depicts all supply chain roles and instances. All conclusions about the risks in the supply chain, like during a strike of an aviation company, where the probability of error increases for all worldwide stations of this company, can be drawn. The market potential includes all pharmaceutical companies operating within Europe. “A risk management for all means of transportation shall be made possible in the long-term, since the tool can be extended in order to include other means of transportation (i.e. sea, train and road transportation). “In the age of digitization and ‘Industry 4.0’ the supply chain will be optimized with respect to the safety and the economy”, emphasizes Ziegler.

The developed prototype of the IT tool shall be transferred into an independently operating company in Germany. The overall costs are estimated to amount to one million Euros; half of this amount will be funded by the project partners. The Federal State Hesse is supporting the practice-oriented research project “Pharma Supply Chain Risk Management in Air Freight” (project number 555/17-37) in the frame of the LOEWE 3 Funding Guidelines with approximately 500,000 Euros.






Viktoriastraße 41
65189 Wiesbaden / Germany